ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

X

Xi'an Jiaotong University

Status and phase

Unknown
Early Phase 1

Conditions

CD19+ Leukemia, B-Cell
CD19+ Lymphoma, B-Cell

Treatments

Biological: ET190L1-ARTEMIS™ T cells -iv low dose
Biological: ET190L1-ARTEMIS™ T cells - iv high dose
Biological: ET190L1-ARTEMIS™ T cells -iv middle dose

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT03895944
XJTU1AF2017LSL-C001

Details and patient eligibility

About

Clinical study to evaluate safety and pharmacokinetics (primary objectives) and efficacy (secondary objective) of ET190L1-ARTEMIS™2 T-cells in patients with Cluster of Differentiation (CD) 19+ B cell Leukemia and Lymphoma

Full description

ARTEMIS™ is a novel chimeric T-cell therapy that in pre-clinical studies, functionally matches the efficacy of Chimeric Antigen Receptor (CAR) T cells, but dramatically reduces the release of cytokines upon killing of target positive tumors. The molecular target for ET190L1-ARTEMIS™ is Cluster of Differentiation 19 (CD19), which is expressed on B cell Lymphomas and B cell Leukemias. ET190L1-ARTEMIS™ is a second generation ARTEMIS™ receptor engineered with a human Fab antibody domain against CD19. This clinical study evaluates the safety and pharmacokinetics of ET190L1-ARTEMIS™ T-cells in patients with relapsed/refractory B-cell lymphoma and B-cell Leukemia.

Enrollment

18 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with relapsed/refractory CD19+ B-cell lymphoma or Leukemia, with no effective therapy available per National Comprehensive Cancer Network (NCCN) guidelines
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2, expected survival time > 3 months per PIs opinion
  • Women of childbearing age should have a negative pregnancy test and agree to use effective contraception during treatment and 1 year after the last dose.
  • Peripheral venous access is available and no issues with apheresis for lymphocyte isolation
  • serum alanine aminotransferase(ALT)<200 Unit/L, ALT/Aspartate aminotransferase(AST)<3 normal range; serum creatinine (Cr)<2.5mg/dL
  • Voluntarily signed informed consent form

Exclusion criteria

  • Women in pregnancy and lactation
  • Unable to perform leukapheresis and iv infusion
  • With active infection
  • Major organ failure
  • Patients with dependence on corticosteroids
  • Continuously used glucocorticoids or other immunosuppressive agents within 2 weeks
  • T cell deficiency or T cells are difficult to be transduced
  • Patients currently receiving other investigational treatments (biotherapy, chemotherapy, or radiotherapy)

Trial design

18 participants in 3 patient groups

iv low dose
Experimental group
Description:
Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with low dose (1x10^6) in Leukemia or Lymphoma patients
Treatment:
Biological: ET190L1-ARTEMIS™ T cells -iv low dose
iv middle dose
Experimental group
Description:
Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with middle dose (3x10^6) in Leukemia or Lymphoma patients
Treatment:
Biological: ET190L1-ARTEMIS™ T cells -iv middle dose
iv high dose
Experimental group
Description:
Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with high dose (10x10^6) in Leukemia or Lymphoma patients
Treatment:
Biological: ET190L1-ARTEMIS™ T cells - iv high dose

Trial contacts and locations

0

Loading...

Central trial contact

Mei Zhang, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems